Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus ISOCAINE HYDROCHLORIDE W LEVONORDEFRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus ISOCAINE HYDROCHLORIDE W LEVONORDEFRIN.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Isocaine hydrochloride (mepivacaine) is an amino amide local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts on alpha-adrenergic receptors to cause local vasoconstriction, prolonging the anesthetic effect.
For local anesthesia: 1-5 mL of 2% solution (20 mg/mL) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Adult dental infiltration or nerve block: 1-2 mL of 2% solution (20 mg/mL isocaine hydrochloride with levonordefrin 1:20,000) administered subcutaneously; maximum single dose 5 mL (100 mg isocaine hydrochloride); maximum total dose 7 mL per appointment.
None Documented
None Documented
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Terminal elimination half-life is approximately 2.1 hours; clinically, accumulation may occur with repeated doses in renal impairment.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Renal excretion of metabolites, primarily 4-hydroxy-2,6-dimethylaniline glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine.
Category C
Category C
Local Anesthetic with Vasoconstrictor
Local Anesthetic with Vasoconstrictor